Navoximod Inhibitor

Name: Navoximod Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5764328
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764328

Navoximod (NLG-919, GDC-0919) is a potent indoleamine-(2,3)-dioxygenase (IDO) pathway inhibitor (Ki/EC50: 7nM/75nM). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Navoximod, Inhibitor

Full Product Name

Navoximod

Product Synonym Names

GDC-0919

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

316.37

Solubility

DMSO: 100mg/mL (316.09mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C18H21FN2O2

SMILES

O[C@H](C[C@@H](c(c-1ccc2)c2F)n2c1cnc2)[C@H](CC1)CC[C@@H]1O

CAS Number

1402837-78-8

Cell Research

Briefly, HeLa cells are seeded in a 96-well plate at a cell density of 5000 cells per well and allowed to grow overnight. Recombinant human IFN-gamma is then added to each well with a final concentration of 50ng/mL. At the same time, various concentrations of PEG2k-Fmoc-NLG(L), PEG2k-Fmoc-NLG(S) or Navoximod (NLG919) (50nM-20uM) are added to the cells. After 48h of incubation, 150uL of the supernatants per well is transferred to a new 96-well plate. Seventy-five uL of 30% trichloroacetic acid is added into each well and the mixture is incubated at 50 degree C for 30min to hydrolyse N-formylkynurenine to kynurenine. For the colorimetric assay, supernatants are transferred to a new 96-well plate, mixed with an equal volume of Ehrlich reagent (2% p-dimethylamino-benzaldehyde w/v in glacial acetic acid), and incubated for 10minutes at RT. The reaction product is measured at 490nm by a plate reader [3].

Product Categories/Family for Navoximod, inhibitor

Metabolism; IDO

Product References and Citations for Navoximod, inhibitor

Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.
Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.
Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21.
Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21.
Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443.
Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443.

Other Notes

Small volumes of Navoximod, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Navoximod purchase

MBS5764328 is an inhibitor targeting Navoximod.